Clinical Trial Update: Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

View source ↗

Summary

A completed trial update examining the prevalence of autoantibodies during checkpoint inhibitor therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Disease
• Cancer

Drugs mentioned

• Checkpoint inhibitors (immune checkpoint inhibitors (PD-1/PD-L1/CTLA-4 inhibitors))

Snippet

Sponsor: CHU de Reims | Conditions: Autoimmune Adverse Effects of Anti-neoplasic Drug | Status: COMPLETED